Cube Click, Inc. announced that its artificial intelligence (AI) dental imaging diagnostic platform SMILE Dx has been approved by the U.S. Food and Drug Administration (FDA).
The platform can assist in the diagnosis of a variety of common dental problems including tooth decay, apical lesions and periodontal disease by analyzing X-ray images.
Cube Click CEO Dr. Richard Ricci pointed out: “The global dental AI imaging market is currently expanding rapidly at a compound annual growth rate of 22.3%.
Even if SMILE Dx only obtains 2% of the market share, annual revenue will reach approximately $62 million. Based on a conservative price-to-sales ratio of 5 times, the company’s valuation can reach $310 million.
If the valuation is 10 times, the potential market value can even reach $620 million. This fully demonstrates the huge appeal of this product to early investors.”
FDA data shows that dentists may misdiagnose tooth decay and root canal lesions in clinical practice. The introduction of SMILE Dx can effectively improve the accuracy of diagnosis.
Clinical data showed that the platform improved detection rates by an average of 19%. The SMILE Dx system is cloud-based and can seamlessly integrate with existing dental imaging equipment, including digital sensors and fluorescent plate sensors.
Other key features of the platform include:
FDA-approved for use with digital and fluorescent plate sensors;
Certified to detect primary, secondary and advanced cavities;
Six U.S. patents issued, with three more patents pending;
Subscription-based cloud platform service for easy scalability and stable recurring revenue.
Cube Click Chief Financial Officer Dr. Andrea Cambria added: “SMILE Dx® is an important technology that is driving change in the dental industry.
Not only does it significantly improve diagnostic capabilities and patient treatment acceptance, it also brings new revenue opportunities to dental practices while establishing a highly scalable subscription model for the company.”
The company said that the development of SMILE Dx is progressing well and is on schedule, with overall costs within budget.
Related topics:
